Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 16Colorectal Neoplasms 7Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Stomach Neoplasms 3Recurrence 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasms 1Neoadjuvant Chemotherapy 1Metastatic Pancreatic Adenocarcinoma 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

Carboplatin 44Paclitaxel 42Cisplatin 20Topotecan 17Gemcitabine 16Docetaxel 13Bevacizumab 13liposomal doxorubicin 7olaparib 6Cyclophosphamide 6pembrolizumab 5Surgical Procedures, Operative 5Filgrastim 5Etoposide 5Drug Therapy 5Amifostine 5sargramostim 4oregovomab 4catumaxomab 4anlotinib 4Imatinib Mesylate 4Hyperthermic Intraperitoneal Chemotherapy 4rucaparib 3pegfilgrastim 3niraparib 3ixabepilone 3aldesleukin 3Standard of Care 3Peripheral Blood Stem Cell Transplantation 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ovarian Epithelial × irinotecan sucrosofate × Clear all
NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡